人卵巢癌细胞PEO4

细胞名称

人卵巢癌细胞PEO4

货物编码

BFN60808598

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研      2类

培养体系

DMEM高糖培养基+10%FBS+1%三抗

培养温度

37℃

二氧化碳浓度

5%

简介

人卵巢癌细胞PEO4取自女性供体腹水。该细胞源于ECACC

注释

Part of: OCCP ovarian cancer cell line panel.

Doubling time: 59 hours (PubMed=3583449); 36 hours (PubMed=3167863).

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep RNAseq analysis.

Omics: Transcriptome analysis.

基因突变

Hemizygous for BRCA2 p.Tyr1655Tyr (5193C>T); de novo mutation that cancels the 5193C>G mutation in the patient (PubMed=19654294).

TP53 p.Gly244Asp (c.731G>A) (PubMed=25230021; PubMed=28273451; DepMap).

HLA信息

Class I

HLA-A        A*03:01,03:01

HLA-B        B*07:02,07:02

HLA-C        C*07:02,07:02

Class II

HLA-DR        DRB1*11:01,04:05

STR信息

Amelogenin        X

CSF1PO        10,12

D2S1338        20,21

D3S1358        16

D5S818        11,12

D7S820        10

D8S1179        13,14

D13S317        10

D16S539        9

D18S51        16,17

D19S433        13,15

D21S11        30,32.2

FGA        20

Penta D        9,14

Penta E        11,12

TH01        9.3

TPOX        9,11

vWA        15,16

参考文献

PubMed=25230021; DOI=10.1371/journal.pone.0103988

Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

PLoS ONE 9:E103988-E103988(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:E954893-E954893(2014)

PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028

Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F., Noonan A.M., Annunziata C.M.

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Gynecol. Oncol. 142:332-340(2016)

PubMed=27561551; DOI=10.1038/ncomms12645

Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.

Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.

Nat. Commun. 7:12645-12645(2016)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028

Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P., Novak M., Doodnauth S.A., Saiz F.S., Cullis J., Al-Awar R., Neel B.G., McPherson J., Drapkin R., Ailles L., Mes-Massons A.-M., Rottapel R.

Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.

Cell Rep. 18:2343-2358(2017)